SUTRO BIOPHARMA, INC.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | $24.5M | $332.0M | $206.2M |
| FY2021 | $15.7M | $252.6M | $30.4M |
| FY2022 | $3.8M | $217.0M | $47.3M |
| FY2023 | $0 | $149.6M | $69.3M |
| FY2024 | — | $44.6M | $190.3M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | $24.5M | $332.0M | $206.2M |
| FY2021 | $15.7M | $252.6M | $30.4M |
| FY2022 | $3.8M | $217.0M | $47.3M |
| FY2023 | $0 | $149.6M | $69.3M |
| FY2024 | — | $44.6M | $190.3M |